Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through…
Oncology
-
-
EC approves extension of indication for Janssen-Cilag’s Darzalex
The European Commission (EC) has approved the extension of indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous (SC) formulation to be…
-
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC)…
-
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to…
-
NBE Therapeutics opens ADC research facility in Switzerland
Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) research and development (R&D) facility in Basel, Switzerland.…
-
Astellas Pharma and JFCR partner for oncology research
Astellas Pharma has entered a strategic partnership with the Japanese Foundation for Cancer Research (JFCR) to expedite research in translational…
-
Amneal and Shilpa introduce Boruzu in US for cancer treatment
Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a…
-
Apollomics and LaunXP agree on NSCLC treatment in Asia
Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined with an epidermal…
-
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as…
-
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene autoleucel…
